SCHEMBL1372354

SCHEMBL1372354

CC(C)(C)OC(=O)N1C[C@H](Cc2ccc(Cl)cc2)C[C@H]1C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX3 P56373 2/20 0.43
ATM Q13315 1/20 0.41
MCL1 Q07820 1/20 0.41
ALDH1A1 P00352 1/20 0.39
NR1H2 P55055 2/20 0.39
NR1H3 Q13133 2/20 0.39
STS P08842 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CTSL P07711 1/20 0.38
CTSB P07858 1/20 0.38
CTSS P25774 1/20 0.38
CTSK P43235 1/20 0.38
OPRK1 P41145 1/20 0.38
S1PR5 Q9H228 1/20 0.38
VEGFA P15692 1/20 0.37
EGLN1 Q9GZT9 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21409110 1.00 P2RX3 (0.43) P2RX3ATMMCL1ALDH1A1NR1H2
SCHEMBL2185184 1.00 P2RX3 (0.43) P2RX3ATMMCL1ALDH1A1NR1H2
SCHEMBL2171522 0.89 CYP2C19 (0.44) P2RX3MCL1NR1H2NR1H3MEN1
SCHEMBL27190612 0.89 CYP2C19 (0.44) P2RX3MCL1NR1H2NR1H3MEN1
SCHEMBL1371521 0.89 CYP2C19 (0.44) P2RX3MCL1NR1H2NR1H3MEN1
SCHEMBL1373084 0.89 NR1H2 (0.48) MCL1NR1H2NR1H3STS
SCHEMBL21409001 0.89 NR1H2 (0.48) MCL1NR1H2NR1H3STS
SCHEMBL6183348 0.89 NR1H2 (0.48) MCL1NR1H2NR1H3STS
SCHEMBL7285245 0.89 NR1H2 (0.48) MCL1NR1H2NR1H3STS
SCHEMBL13687997 0.89 NR1H2 (0.48) MCL1NR1H2NR1H3STS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791102-B2 Acetanilide sphingosine-1-phosphate receptor antagonists EXELIXIS, INC. (US) 2014-07-29 US disclosed
US-20110288076-A1 Sphingosine-1-Phosphate Receptor Antagonists EXELIXIS, INC. (US) 2011-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110288076-A1 Sphingosine-1-Phosphate Receptor Antagonists S1PR1, S1PR2, S1PR3 P2RX3 475/4885ATM 1900/4885MCL1 377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.